Reproxalap

Reproxalap achieved the primary endpoint of improved ocular redness in patients with dry eye disease in a phase 2 clinical trial, according to a press release from Aldeyra Therapeutics.

AMELIA ISLAND, Fla. — Reproxalap, an inhibitor to reactive aldehyde species, may be a critical tool in the future of treating a number of ocular inflammatory conditions, according to a presentation at Cataract Surgery: Telling It Like It Is.

Aldeyra Therapeutics has released positive topline results from a phase 3 clinical trial investigating reproxalap in patients with allergic conjunctivitis, according to a press release.

Reproxalap demonstrated statistically significant improvements in dry eye symptoms, redness and Schirmer’s test results compared with vehicle in a run-in cohort of the phase 3 TRANQUILITY clinical trial, Aldeyra Therapeutics announced.

The first patient has been enrolled in the phase 3 TRANQUILITY trial evaluating reproxalap for the treatment of patients with dry eye disease, according to a press release from Aldeyra Therapeutics.

Aldeyra Therapeutics has received a “study may proceed” letter from the FDA for a phase 2 clinical trial evaluating ADX-629 as a treatment for adult patients hospitalized with COVID-19, according to a press release.